Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 327287, 12 pages
http://dx.doi.org/10.1155/2015/327287
Research Article

MicroRNA-155 Hallmarks Promising Accuracy for the Diagnosis of Various Carcinomas: Results from a Meta-Analysis

1Department of Preventive Medicine, Fujian Province Key Lab of Environment and Health, Institution of Environment and Health, Major Subject of Environment and Health of Fujian Key Universities, School of Public Health, Fujian Medical University, No. 1 Xue Yuan Road, University Town, Fuzhou, Fujian 350108, China
2School of Postgraduate Education, Fujian Medical University, No. 1 Xue Yuan Road, University Town, Fuzhou, Fujian 350108, China

Received 24 December 2014; Accepted 27 February 2015

Academic Editor: Marco E. M. Peluso

Copyright © 2015 Chuancheng Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Luo, L. Y. Dong, Q. G. Yan et al., “Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer,” Asian Pacific Journal of Cancer Prevention, vol. 15, pp. 8529–8538, 2014. View at Google Scholar
  2. H. M. Heneghan, N. Miller, R. Kelly, J. Newell, and M. J. Kerin, “Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease,” Oncologist, vol. 15, no. 7, pp. 673–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Harris, H. Fritsche, R. Mennel et al., “American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5287–5312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Gao, Q. Zhang, J. Xu, L. Guo, and X. Li, “Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA,” Chinese Journal of Cancer Research, vol. 25, no. 6, pp. 743–748, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. I. M. Thompson, D. K. Pauler, P. J. Goodman et al., “Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2239–2246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. G. A. Calin and C. M. Croce, “MicroRNA signatures in human cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Marcucci, K. Mrózek, M. D. Radmacher, C. D. Bloomfield, and C. M. Croce, “MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias,” Best Practice and Research: Clinical Haematology, vol. 22, no. 2, pp. 239–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Cheng, “Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy,” Advanced Drug Delivery Reviews, vol. 81, pp. 75–93, 2015. View at Publisher · View at Google Scholar
  9. J. Hayes, P. P. Peruzzi, and S. Lawler, “MicroRNAs in cancer: biomarkers, functions and therapy,” Trends in Molecular Medicine, vol. 20, no. 8, pp. 460–469, 2014. View at Publisher · View at Google Scholar
  10. C. Hou, G. Tan, and S. Feng, “Clinical significance of microRNA expressions in diagnosing uterine cancer and predicting lymph node metastasis,” Tumor Biology, vol. 35, no. 11, pp. 10789–10798, 2014. View at Publisher · View at Google Scholar
  11. Z. Cui and D. Lin, “Circulating miRNAs: potential biomarkers for diagnosis and prognosis prediction of hematological malignancies,” Journal of Leukemia, vol. 2, article 140, 3 pages, 2014. View at Publisher · View at Google Scholar
  12. C. Fang, D.-X. Zhu, H.-J. Dong et al., “Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma,” Annals of Hematology, vol. 91, no. 4, pp. 553–559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Jay, J. Nemunaitis, P. Chen, P. Fulgham, and A. W. Tong, “miRNA profiling for diagnosis and prognosis of human cancer,” DNA and Cell Biology, vol. 26, no. 5, pp. 293–300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Mattiske, R. J. Suetani, P. M. Neilsen, and D. F. Callen, “The oncogenic role of miR-155 in breast cancer,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 8, pp. 1236–1243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Chen, T. Ma, C. Huang, T. Hu, and J. Li, “The pivotal role of microRNA-155 in the control of cancer,” Journal of Cellular Physiology, vol. 229, no. 5, pp. 545–550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Higgs and F. Slack, “The multiple roles of microRNA-155 in oncogenesis,” Journal of Clinical Bioinformatics, vol. 3, no. 1, article 17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Sun, M. Wang, G. Lin et al., “Serum microRNA-155 as a potential biomarker to track disease in breast cancer,” PLoS ONE, vol. 7, no. 10, Article ID e47003, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Mar-Aguilar, J. A. Mendoza-Ramírez, I. Malagón-Santiago et al., “Serum circulating microRNA profiling for identification of potential breast cancer biomarkers,” Disease Markers, vol. 34, no. 3, pp. 163–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Zhao, Q. Wu, F. Gao, C. Zhang, and X. Yang, “Serum microRNA-155 as a potential biomarker for breast cancer screening,” Chinese Science Bulletin, vol. 57, no. 26, pp. 3466–3468, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. T. Xie, Z. X. Chu, and H. Wang, “Serum microRNA expression profile as a biomarker in diagnosis and prognosis of acute myeloid leukemia,” Journal of Clinical Pediatric Dentistry, vol. 30, no. 5, pp. 421–424, 2012. View at Google Scholar
  21. W. Z. Pan, W. Y. Tang, W. Yuan et al., “Expression and clinical significance of plasma small RNA in patients with pancreatic cancer,” Chinese Journal of Oncology, vol. 36, no. 5, pp. 351–354, 2014. View at Google Scholar
  22. J. Wang, J. Chen, P. Chang et al., “MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease,” Cancer Prevention Research, vol. 2, no. 9, pp. 807–813, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. A. Abd-El-Fattah, N. A. H. Sadik, O. G. Shaker, and M. L. Aboulftouh, “Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia,” Cell Biochemistry and Biophysics, vol. 67, no. 3, pp. 875–884, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Gao, J. Chang, H. Wang, and G. Zhang, “Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients,” Oncology Reports, vol. 31, no. 1, pp. 351–357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Tang, Y. Shen, M. Wang et al., “Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer,” European Journal of Cancer Prevention, vol. 22, no. 6, pp. 540–548, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Liu, J. Liao, M. Yang et al., “Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans,” Journal of Toxicology and Environmental Health Part A: Current Issues, vol. 75, no. 18, pp. 1154–1162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Yang, T. Tang, W. Peng et al., “The comparison of miR-155 with computed tomography and computed tomography plus serum amyloid A protein in staging rectal cancer,” Journal of Surgical Research, vol. 193, no. 2, pp. 764–771, 2015. View at Publisher · View at Google Scholar
  28. K. Gombos, R. Horváth, E. Szele et al., “miRNA expression profiles of oral squamous cell carcinomas,” Anticancer Research, vol. 33, no. 4, pp. 1511–1517, 2013. View at Google Scholar · View at Scopus
  29. S. F. M. Häusler, A. Keller, P. A. Chandran et al., “Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening,” British Journal of Cancer, vol. 103, no. 5, pp. 693–700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. W. H. Roa, J. O. Kim, R. Razzak et al., “Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer,” Clinical and Investigative Medicine, vol. 35, no. 5, pp. E271–E281, 2012. View at Google Scholar · View at Scopus
  31. D. Zheng, S. Haddadin, Y. Wang et al., “Plasma micrornas as novel biomarkers for early detection of lung cancer,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 6, pp. 575–586, 2011. View at Google Scholar · View at Scopus
  32. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” Journal of Clinical Epidemiology, vol. 62, pp. 1006–1012, 2009. View at Google Scholar
  33. P. Whiting, A. W. S. Rutjes, J. B. Reitsma, P. M. M. Bossuyt, and J. Kleijnen, “The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews,” BMC Medical Research Methodology, vol. 3, article 25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Zamora, V. Abraira, A. Muriel, K. Khan, and A. Coomarasamy, “MetaDiSc: a software for meta-analysis of test accuracy data,” BMC Medical Research Methodology, vol. 6, article 31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. S. Glas, J. G. Lijmer, M. H. Prins, G. J. Bonsel, and P. M. M. Bossuyt, “The diagnostic odds ratio: a single indicator of test performance,” Journal of Clinical Epidemiology, vol. 56, no. 11, pp. 1129–1135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Cui, D. Lin, W. Song, M. Chen, and D. Li, “Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study,” Tumour Biology, vol. 36, no. 2, pp. 829–839, 2015. View at Publisher · View at Google Scholar
  37. F. Wang, J. Hou, W. Jin et al., “Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis,” Molecules, vol. 19, no. 5, pp. 6282–6293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. Li, L. Liu, and W. Li, “Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis,” Tumor Biology, vol. 35, no. 10, pp. 10467–10478, 2014. View at Publisher · View at Google Scholar
  39. K. Wang, Y. Yuan, J.-H. Cho, S. McClarty, D. Baxter, and D. J. Galas, “Comparing the MicroRNA spectrum between serum and plasma,” PLoS ONE, vol. 7, no. 7, Article ID e41561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Zhao, J. Shen, L. Medico, D. Wang, C. B. Ambrosone, and S. Liu, “A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer,” PLoS ONE, vol. 5, no. 10, Article ID e13735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Hu, X. Chen, Y. Zhao et al., “Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1721–1726, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Hongliang, H. Shaojun, L. Aihua, and J. Hua, “Correlation between expression of miR-155 in colon cancer and serum carcinoembryonic antigen level and its contribution to recurrence and metastasis forecas,” Saudi Medical Journal, vol. 35, pp. 547–553, 2014. View at Google Scholar